139 related articles for article (PubMed ID: 9239501)
1. In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.
Erwin ME; Varnam D; Jones RN
Diagn Microbiol Infect Dis; 1997 Jun; 28(2):93-100. PubMed ID: 9239501
[TBL] [Abstract][Full Text] [Related]
2. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
Neu HC; Chin NX; Huang HB
Antimicrob Agents Chemother; 1993 Mar; 37(3):566-73. PubMed ID: 8460925
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
[TBL] [Abstract][Full Text] [Related]
6. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
7. Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.
Murphy SP; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1994 Sep; 20(1):49-55. PubMed ID: 7867299
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.
Hata K; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1992 Sep; 36(9):1894-901. PubMed ID: 1416879
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
11. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
Jones RN; Erwin ME
Antimicrob Agents Chemother; 1992 Jan; 36(1):233-8. PubMed ID: 1590695
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of RU 29246, the active compound of the cephalosporin prodrug ester HR 916.
Riess G; Andrews J; Thornber D; Wise R
Antimicrob Agents Chemother; 1992 Nov; 36(11):2360-4. PubMed ID: 1489178
[TBL] [Abstract][Full Text] [Related]
15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
[TBL] [Abstract][Full Text] [Related]
17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
